Colossal Biosciences

Colossal Biosciences is a biotech and genetic engineering company founded in 2021 in Austin, Texas. Their work combines CRISPR gene editing, synthetic biology, and reproductive technology, making it one of the most ambitious biotech projects today.

The company’s main goal is de-extinction, which means rebuilding the DNA of lost species and creating living versions using the genomes of their closest relatives. Colossal is the first to use CRISPR technology for this, starting with the woolly mammoth. They’re also working on the Tasmanian tiger, dodo, dire wolf, and northern white rhinoceros. Besides de-extinction, they develop tools to protect endangered species and restore ecosystems. Their spin-offs include Form Bio, a computational life sciences platform, and Breaking, a startup that uses engineered microbes and enzymes to break down plastic.

Since it started, Colossal has grown quickly. It raised $15 million in seed funding in September 2021, $60 million in Series A in March 2022, and $150 million in Series B in January 2023. In January 2025, it secured $200 million in Series C funding, reaching a $10.2 billion valuation and becoming Texas’s first decacorn. A $120 million extension in September 2025 raised the Series C total to $320 million and the valuation to $10.32 billion. On the science side, April 2025 was a milestone when Colossal announced the birth of three dire wolf pups (named Romulus, Remus, and Khaleesi), calling them the world’s first successfully de-extincted animals.

Colossal’s investors come from Hollywood, Silicon Valley, and institutional finance. Key backers include TWG Global, which led the Series C round, along with USIT, Bob Nelsen, and filmmaker Peter Jackson, who joined the Series C extension. With over 78 investors, the company shows strong confidence in its science and long-term business potential.

Since Colossal Biosciences is pre-IPO, its shares aren’t on public exchanges yet. But you can still get involved. Acquire.Fi lets you join the private market by connecting directly with early investors and team members who want to sell their shares before the company goes public.

Buying Colossal Biosciences stock pre-IPO is simple. You can look through current sell offers on the marketplace and choose terms that suit you, or create a new Buy listing with your target amount and preferred price.

Minority shareholders who want to sell Colossal Biosciences stock pre-IPO are also welcome. You can check offers from qualified buyers on the marketplace or set your own terms by creating a new Sell listing.

Acquire.Fi stands out by adding structure and trust to a market that’s often unclear and scattered. Private share deals usually happen through informal channels like Telegram or Discord, where buyers and sellers aren’t verified and the process is unorganized. Acquire.Fi changes that by offering a vetted marketplace with transparent offers, screened participants, and a team that guides every transaction from start to finish.